# First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis

> **NCT07527923** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Regeneron Pharmaceuticals** · enrollment: 136 (estimated)

## Conditions studied

- Healthy Volunteer
- Atopic Dermatitis

## Interventions

- **DRUG:** REGN20423
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT07527923
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05-04
- **Primary completion:** 2028-06-09
- **Final completion:** 2028-06-09
- **Target enrollment:** 136 (ESTIMATED)
- **Last updated:** 2026-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07527923

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07527923, "First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07527923. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*